Featured Question

What nuances related to dosing and pharmacokinetics of the GLP-1–based therapies should clinicians be aware of, and how do the short- and long-acting agents differ in terms of their characteristics and use? Should this class of therapies be used as monotherapy or as part of combination regimens?

See The Answer

Get the latest
science delivered
to your inbox

Answers in CME updates are
available in YOUR specialty.

Sign-up Now!

Featured Activities

09-17-2015

Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on Appropriate Patient Selection and Nuances of Clinical Use

Course Director
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center,
Temple Health
Philadelphia, Pennsylvania

09-11-2015

Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on the Current State of the Science and Implications for Practice

Course Director
Elizabeth R. Plimack, MD, MS
Fox Chase Cancer Center,
Temple Health
Philadelphia, Pennsylvania

06-08-2015

Individualized Treatment Selection for Patients With Type 2 Diabetes: Considering the Role of the GLP-1 Receptor Agonists in the Context of Other Therapies

Course Director
Guillermo E. Umpierrez, MD, CDE, FACP, FACE
Emory University
Grady Health System
Atlanta, Georgia

05-13-2015

Challenging Cases in Schizophrenia: Considerations for Individualized Treatment Selection

Course Director
Christoph U. Correll, MD
Hofstra North Shore LIJ School of Medicine
The Zucker Hillside Hospital
Glen Oaks, New York

05-12-2015

Current Perspectives on the Evolving Treatment Landscape in Schizophrenia and Practical Recommendations for Improving Patient Care

Course Director
Christoph U. Correll, MD
Hofstra North Shore LIJ School of Medicine
The Zucker Hillside Hospital
Glen Oaks, New York

05-06-2015

Assessing the Benefits and Limitations of the GLP-1 Receptor Agonists in the Management of Type 2 Diabetes

Course Director
Guillermo E. Umpierrez, MD, CDE, FACP, FACE
Emory University
Grady Health System
Atlanta, Georgia

04-29-2015

Current Perspectives in Management of Hypercholesterolemia: Practical Considerations for Screening and Treatment Selection

Course Director
Peter P. Toth, MD, PhD, FAAFP, FNLA, FICA, FCCP, FAHA, FACC
CGH Medical Center
Sterling, Illinois
University of Illinois
College of Medicine
Peoria, Illinois
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
Johns Hopkins University
School of Medicine
Baltimore, Maryland

04-27-2015

New and Emerging Treatment Options for Hypercholesterolemia: Evaluating the Characteristics, Benefits, Limitations, and Potential Roles

Course Director
Peter P. Toth, MD, PhD, FAAFP, FNLA, FICA, FCCP, FAHA, FACC
CGH Medical Center
Sterling, Illinois
University of Illinois
College of Medicine
Peoria, Illinois
Michigan State University
College of Osteopathic Medicine
East Lansing, Michigan
Johns Hopkins University
School of Medicine
Baltimore, Maryland

04-17-2015

Challenging Cases in Advanced Colorectal Cancer: Considering the Latest Evidence and Patient Preferences as Part of Shared Decision-Making

Course Director
Johanna C. Bendell, MD
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

04-15-2015

Considering the Latest Evidence and Factors to Guide Individualized Treatment Planning in Metastatic Colorectal Cancer

Course Director
Johanna C. Bendell, MD
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee